Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Hematological Malignancy, Polycythemia Vera, Essential Thrombocythemia +11

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 856 citations · Full text

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 734 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Richard M. Stone, Daniel J. DeAngelo, Virginia M. Klimek et al. · Blood · 2004 · 659 citations · Full text